ERBB2 and breast carcinoma: Because of the limited use of molecular detection in Chinese patients, the abilities of Oncotype and PAM50 to accurately predict prognosis in patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative early breast cancer have not been compared.